LUGANO- SINGAPORE – The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, is pleased to announce the fourth ESMO Asia 2018 Congress. Held 23–25 November 2018 at the Suntec Convention and Exhibition Centre in Singapore, the scientific and educational congress will keep oncology professionals in the Asia-Paciﬁc region up to date with the fast pace of oncology science and education, and provide important networking opportunities with international peers.
Clear trends in providing ultimate cancer care emerge from the ESMO Asia 2018 Programme where international studies will be presented with an eye on providing useful perspectives for local practitioners. Among the 578 accepted abstracts, you may find of particular interest:
- Primary erfficacy and safety results of adding atezolizumab to standard treatment of patients with extensive stage NSCLC: the Impower133 trial
- Primary results of a phase III, randomised open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC: the ALESIA Trial
- Results of maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation: the SOLO1 trial
The congress programme features numerous sessions in which global leaders will present the latest knowledge on state-of-the-art treatment of cancer, such as:
- Immunotherapy in gastrointestinal cancers: Current status & future perspectives
- Multidisciplinary approach to resectable gastric cancer
- Challenges in head and neck cancer
- Optimal management of locally advanced nasopharyngeal carcinoma
- Integrating BRCA testing into routine cancer care in Asia – how can it be done?
- Controversies in lung cancer immuno-oncology
- Management of early breast cancer in young women
- Issues for cancer care in the elderly
If your focus is not only clinical, you can follow thought-provoking debates:
- The reality of accessing cancer care in Asia and Asia/Pacific
- The challenges of cancer care in low and middle-income countries
- Adaptation of the ESMO Clinical Practice Guidelines in Asia
- Rare cancers: a call to advancing partnerships between Asia and Europe
The ESMO Asia 2018 Congress is expected to draw around 3,000 participants and is supported by 21 oncology associations in the region, including the Singapore Society of Oncology and oncology societies from Australia, Bangladesh, China, Hong Kong, India, Indonesia, Iran, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, South Korea, Taiwan, Thailand and Uzbekistan.
ESMO welcomes members of the press interested in reporting on cancer. Registration to the ESMO Asia 2018 Congress is free to bona fide journalists on presentation of a letter of assignment and a valid press card.
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO Asia 2018 Congress
Official Congress Hashtag: #ESMOAsia18
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 20,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.